Welcome to our dedicated page for Incyte Corporation news (Ticker: $INCY), a resource for investors and traders seeking the latest updates and insights on Incyte Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Incyte Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Incyte Corporation's position in the market.
Incyte (Nasdaq: INCY) will present multiple abstracts from its oncology portfolio at the 2024 ASCO Annual Meeting (May 31 – June 4) and EHA2024 Congress (June 13-16). Key studies include:
ASCO: INCB099280 - Phase 1 Small-Molecule PD-L1 inhibitor study, INCB057643 - Phase 1 BET inhibitor study.
EHA: Ruxolitinib - Multiple studies on Polycythemia Vera and Myelofibrosis, Zilurgisertib - ALK2 inhibitor studies, INCB160058 - Novel therapy for JAK2V617F mutant Myeloproliferative Neoplasms, Axatilimab - Graft-Versus-Host Disease study, Pemigatinib - Phase 2 study on Myeloid/Lymphoid Neoplasms, Tafasitamab - CD19 expression in Diffuse Large B-Cell Lymphoma.
These presentations highlight Incyte's commitment to developing new cancer treatments.
Incyte announced a $2.0 billion share repurchase authorization, with a Dutch Auction tender offer to repurchase up to $1.672 billion of outstanding common shares. The offer reflects confidence in the company's future outlook, product portfolio, and clinical pipeline. A separate stock purchase agreement with Baker Entities will repurchase up to $328.0 million of common stock, enabling them to maintain their ownership level. The tender offer, expiring on June 10, 2024, allows stockholders to tender shares within a price range for repurchase.
Incyte (Nasdaq:INCY) will be presenting at the Bank of America Securities 2024 Health Care Conference on May 15, 2024, in Las Vegas. The presentation will be webcast live and available for replay for 30 days.
Incyte reports total revenues of $881 million in Q1'24, up 9% Y/Y, with Jakafi® net product revenues at $572 million, Opzelura® at $86 million, and plans to acquire Escient Pharmaceuticals. The company made progress with clinical pipeline and key agreements for drug development.